In December 2019, a new coronavirus (COVID-19) was discovered due to atypical viral pneumonia cases in Wuhan. In early January 2020, Synbio Technologies designed and synthesized detection probes for COVID-19 based on our independently developed Syno® qPCR primer/probe design and synthesis platform. In less than two weeks, we completed the synthesis of detection reagent materials, such as amplification primers, probes, and quality controls. Since the outbreak of COVID-19, Synbio Technologies has set up a special coronavirus emergency project team, working against time to produce virus-related probes, genes, and protein products. We are currently working with our clients and partners from hospitals, scientific research institutes, and upstream & downstream enterprises to fight the disease. We use our efforts to realize the company’s vision of “Genes for Life.” We hope that, through Synbio Technologies’s synthetic technology platforms, we can accelerate virus research and help benefit each patient’s life as soon as possible.
- Speed guarantee: All COVID-19 related orders will be given priority to green channel production, with 24/7 professional online support.
- Quality assurance: ISO 13485 standards of manufacturing, high-quality raw materials, zero cross-contamination, and perfect track records.
- Production capacity guarantee: experienced synthesis experts, first in class instruments, more than one million probe kit materials supplied per day.
Probe/Primer Synthesis for Virus DetectionAccording to the official website documents of WHO and China CDC, Synbio Technologies has prepared a series of primers and probe materials for COVID-19 detection in batches. We can provide a free trial package and guarantee the supply of a million copies of nucleic acid diagnostic probes daily to speed up disease detection and research.Set 01：
|RdRP gene||1||Primer RdRP_SARSr-F2||GTGARATGGTCATGTGTGGCGG|
|E gene||5||Primer E_Sarbeco_F1||ACAGGTACGTTAATAGTTAATAGCGT|
|Target 1（ORF1ab）||11||Forward Primer 1ab||CCCTGTGGGTTTTACACTTAA|
|12||Reverse Primer 1ab||ACGATTGTGCATCAGCTGA|
|Target 2（N）||14||Forward Primer N||GGGGAACTTCTCCTGCTAGAAT|
|15||Reverse Primer N||CAGACATTTTGCTCTCAAGCTG|
|Endogenous control||17||RNAse P-20013001||AGATTTGGACCTGCGAGCG|
Gene Synthesis & Protein Expression for COVID-19
Synbio Technologies’ Syno® DNA synthesis platform provides fast gene and fragment synthesis, high-throughput synthesis, metabolic pathways, gene assembly, etc. The independently developed CI sequence difficulty index system can facilitate the accurate, fast, and high-quality synthesis of any sequence. Currently, we have completed the synthesis of all structural and non-structural protein genes or gene fragments of the COVID-19. This has promoted the acquisition of the virus recombinant proteins and the research of its protein structural biology. The virus-related target gene synthesis has been mass-produced, and can be delivered directly for research use only.
|RdRP gene standards （plasmid）||GTGAAATGGTCATGTGTGGCGGTTCACTATATGTTAAACCAGGTGGAACCTCATCAGGAGATGCCACAACTGCTTATGCTAATAGT|
|E gene standards （plasmid）||ACAGGTACGTTAATAGTTAATAGCGTACTTCTTTTTCTTGCTTTCGTGGTATTCTTGCTAGTTACACTAGCCATCCTTACTGCGCTTCGATTGTGTGC|
|N gene standards1 （plasmid）||CACATTGGCACCCGCAATCCTGCTAACAATGCTGCAATCGTGCTACAACTTCCTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAG|
|N gene standards2 （plasmid）||GGGGAACTTCTCCTGCTAGAATGGCTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATTGAACCAGCTTGAG|
|ORF1ab gene standards （plasmid）||CCCTGTGGGTTTTACACTTAAAAACACAGTCTGTACCGTCTGCGGTATGTGGAAAGGTTATGGCTGTAGTTGTGATCAACTCCGCGAACCCATGCTT|
* For more sequence information, please contact email@example.com